Skip to main content
HR 1774 114th Congress House Health Administrative law and regulatory procedures Alternative treatments Department of Justice Drug Enforcement Administration (DEA) Drug trafficking and controlled substances Drug, alcohol, tobacco use Intergovernmental relations Medical research Prescription drugs Research administration and funding State and local government operations

Compassionate Access Act

Introduced: April 14, 2015 Introduced by: Griffith, H. Morgan Republican · Virginia See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 15, 2015
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Apr 17, 2015
Referred to the Subcommittee on Health.
Apr 14, 2015
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 14, 2015
Introduced in House
 Plain-English summary Congressional Research Service

Compassionate Access Act

This bill directs the Department of Health and Human Services to submit to the Drug Enforcement Administration (DEA) a recommendation to transfer marijuana from schedule I to another controlled substances schedule. The DEA must consider the recommendation and issue a final rule to reclassify marijuana.

It permits, for reclassification purposes, consideration of scientifically sound research conducted in a state that allows medical marijuana and in accordance with state law, even if such research uses non-federally approved marijuana.

The legislation amends the Controlled Substances Act (CSA) to:

  • exclude "cannabidiol" (CBD) from the definition of "marijuana" and remove it from coverage under the CSA;
  • limit the concentration of delta-9-tetrahydrocannabinol (THC) in CBD to 0.3% on a dry weight basis; and
  • deem marijuana grown or processed to make CBD, in accordance with state law, to comply with the THC concentration limit unless the DEA determines state law to be unreasonable.

No provision of the CSA or Federal Food, Drug, and Cosmetic Act prohibits or restricts a physician from prescribing; a patient, caregiver, or guardian from obtaining, possessing, or transporting; an entity from producing, processing, manufacturing, or distributing; a pharmacy from dispensing; or a laboratory from testing medical marijuana or CBD in compliance with a state's medical marijuana law.

The bill requires the Attorney General to delegate responsibility for registering marijuana researchers to an executive branch agency that supports research on substances' medical value. Such agency must ensure adequate marijuana supply for medical research.


What's happening now May 15, 2015

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

 Committees of jurisdiction 4